Article Is Letting You Know In Advance Halo Great Study. Big Gains at Asco.
Halozyme To Present New Data On PEGPH20 In Pancreatic Cancer At American Society Of Clinical Oncology Annual Meeting
BY PR Newswire | 05/16/13
Stock quotes in this article: HALO
"Data from this single arm Phase 1b study clearly reinforce the hypothesis of treating pancreatic cancer with PEGPH20 in conjunction with chemotherapeutic agents," said Joy Zhu, M.D., Ph.D., Vice President,OncologyClinical Development, Halozyme. "We look forward to the study investigators presenting the updated study results at the poster session and ensuing discussion